1. Home
  2. Products
  3. Customized ADCs
  4. TNFRSF8
  5. Anti-TNFRSF8-DIBO-doxorubicin ADC-12

Anti-TNFRSF8-DIBO-doxorubicin ADC-12 (CAT#: ADC-W-340)

This ADC product is comprised of an anti-TNFRSF8 monoclonal antibody (cAC10) conjugated via a DIBO linker to a doxorubicin. The doxorubicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, doxorubicin binds to DNA, causes DNA damage.

  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Name
  • TNFRSF8
  • Alternative Names
  • TNFRSF8; tumor necrosis factor receptor superfamily, member 8; CD30; Ki-1; D1S166E; tumor necrosis factor receptor superfamily member 8; Ki-1 antigen; CD30L receptor; cytokine receptor CD30; lymphocyte activation antigen CD30;
  • Target Entrez Gene ID
  • 943
  • Overview
  • The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
  • Overview
  • Chimeric Anti-TNFRSF8 Antibody, cAC10
  • Generic name
  • cAC10
  • Species Reactivity
  • Human
  • Name
  • DIBO (dibenzylcyclooctynol)
  • Name
  • doxorubicin
  • Description
  • Doxorubicin is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform
Reviews
Development of Monoclonal Antibodies
Literature
CAMouse™-Fully Human Antibody Generation Platform
Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-340. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins
Drug-linker Complexes
Customized ADCs
Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-509 Anti-TNFRSF8 (Brentuximab)-VC-PABC-MMAE ADC VC-PABC(valine-citrulline-p-aminobenzylcarbamate) MMAE (Monomethyl auristatin E)
ADC-W-1891 Anti-TNFRSF8 (Iratumumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-355 Anti-TNFRSF8 -Mc-MMAF ADC-12 MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAF (Monomethyl auristatin F)
ADC-W-1887 Anti-TNFRSF8 (Iratumumab)-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-1890 Anti-TNFRSF8 (Iratumumab)-MC-Vc-PAB-SN38 ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) SN-38 (7-ethyl-10-hydroxycamptothecin)
CAT# Product Name Linker Payload
ADC-W-339 Anti-CD22-DIBO-doxorubicin ADC DIBO (dibenzylcyclooctynol) doxorubicin
CAT# Product Name Linker Payload
ADC-W-571 Anti-ERBB2 (Trastuzumab)-DOX ADC thiomaleamicacids-p-aminobenzyloxycarbonyl doxorubicin
ADC-W-378 Anti-CD74-hindered disulfide-Doxorubicin ADC hindered disulfide doxorubicin
ADC-W-339 Anti-CD22-DIBO-doxorubicin ADC DIBO (dibenzylcyclooctynol) doxorubicin
ADC-W-600 Anti-EGFR-doxorubicin ADC polyethylene glycol linker doxorubicin
ADC-W-504 Anti-EGFR (cetuximab)-SMCC-Doxorubicin ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) Doxorubicin

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Online Inquiry

Name:
Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.